AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Werewolf Therapeutics, Inc. Director's Dealing 2021

Apr 29, 2021

34192_dirs_2021-04-29_f669346a-c117-4e3d-b8c3-3dd998696fc2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2021-04-29

Reporting Person: Morrison Briggs (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	15523	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$1.56	2029-12-12	Common Stock (31047)		Direct

Footnotes

F1: The option was granted on December 13, 2019 with a Vesting Commencement date of November 13, 2019. The shares underlying the option vest over four years in equal monthly installments through November 13, 2023.